


Last Close 8.56 (CAD)	Avg Daily Vol 1.4M	52-Week High 17.86	Trailing PE --	Annual Div --	ROE -0.3%	LTG Forecast --	1-Mo Return 5.8%
2017 June 22 TORONTO Exchange	Market Cap 1.3B	52-Week Low 2.62	Forward PE --	Dividend Yield --	Annual Rev 30M	Inst Own 1.9%	3-Mo Return -11.9%

AVERAGE SCORE

AVERAGE SCORE
6

NEUTRAL OUTLOOK: WEED's current score is relatively in-line with the market.



Score Averages

Pharmaceuticals Group:	5.2	Mid Market Cap:	7.5
Pharma. & Med. Research Sector:	4.2	TSX Comp Index:	7.5

Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
WEED	6	7	6	6	6	
ICC	NR	5	5	3	5	
ACB	5	7	4	5	4	
MJN	3	6	4	3	2	
FIRE	NR	NR	NR	NR	NR	

HIGHLIGHTS


- The score for Canopy Growth Corp last changed from 5 to 6 on 2017-06-11.
- The recent change in the Average Score was primarily due to an improvement in the Price Momentum component score.

THOMSON REUTERS I/B/E/S MEAN


Buy

9 Analysts

Mean recommendation from all analysts covering the company on a standardized 5-point scale.



PRICE AND VOLUME CHARTS



BUSINESS SUMMARY


Canopy Growth Corporation, formerly Tweed Marijuana Inc., is a diversified cannabis company. The Company, through its subsidiaries Tweed Inc. (Tweed), Bedrocan Canada Inc. (Bedrocan) and Tweed Farms Inc. (Tweed Farms), is engaged in the business of producing and selling legal marijuana in the Canadian medical market. It is also focusing on producing and selling marijuana in the recreational market in Canada. Its core brands are Tweed and Bedrocan. Tweed is a licensed producer of medical marijuana. Tweed's commercial license covers approximately 168,000 square feet of its Smiths Falls facility and allows Tweed to produce and sell approximately 3,540 kilograms of medical marijuana per year. Tweed's built-out production capacity is over 10 climate controlled indoor growing rooms. Bedrocan is a medical-grade cannabis. Bedrocan's over 52,000 square feet production facility in Toronto, Ontario is licensed, and includes over 30 vegetative and growing rooms, and over three dispensing rooms.



INDICATOR COMPONENTS

AVERAGE SCORE
6

The **AVERAGE SCORE** combines the quantitative analysis of five widely-used investment decision making tools: Earnings, Fundamental, Relative Valuation, Risk, and Price Momentum. A simple average of the underlying component ratings is normally distributed to rank stocks on a 1-10 scale (10 being awarded to the most favorable). These factors may be evaluated differently using alternative methodologies and the importance of individual factors varies across industries, market capitalization and investment styles. Additional criteria should always be used to evaluate a stock.



PEER ANALYSIS

Currency in CAD

Average Score	Ticker	PRICE MOMENTUM				VALUATION		FUNDAMENTAL		ANALYSTS		# of Analysts	
		Price (2017-06-22)	1-Mo Return	3-Mo Return	1-Yr Return	Market Cap	Trailing PE	Forward PE	Dividend Yield	Net Margin	LTG Forecast		I/B/E/S Mean
7	VRX	20.51	11.8%	43.9%	-26.0%	5.7B	--	4.3	--	-14.9%	-9.2%	Hold	7
6	GUD	10.18	1.5%	2.5%	25.1%	1.4B	56.6	66.5	--	629.9%	--	Buy	10
6	WEED	8.56	5.8%	-11.9%	199.3%	1.3B	--	--	--	-2.1%	--	Buy	9
2	PLI	1.80	-12.6%	-18.6%	-37.1%	1.1B	--	--	--	-697.3%	--	Buy	11
7	APH	5.65	-0.5%	-9.6%	271.7%	744M	70.6	108.7	--	46.3%	--	Buy	7
4	ACB	2.19	-12.8%	-3.5%	356.3%	717M	--	--	--	-117.0%	--	Strong Buy	2
7	TH	7.76	18.7%	46.1%	180.1%	530M	776.0	--	--	-4.5%	--	Buy	7
4	OGI	2.27	-12.0%	6.6%	110.2%	229M	227.0	--	--	-103.7%	--	Buy	7
2	MJN	1.75	-21.9%	-33.2%	775.0%	225M	--	--	--	-144.6%	--	Buy	5
NR	FIRE	1.32	2540%	2540%	2540%	204M	--	--	--	--	--	Buy	5
NR	ZOM	2.35	-6.0%	63.2%	158.2%	203M	--	--	--	--	--	--	--
5	Average	5.85	228.4%	238.7%	413.9%	1.1B	282.5	59.8	--	-45.3%	-9.2%	Buy	7

PEER COMPANIES

VRX	Valeant Pharmaceuticals	TH	Theratechnologies Inc
GUD	Knight Therapeutics Inc	OGI	OrganiGram Holdings Inc
PLI	Prometic Life Sciences Inc	MJN	Cronos Group Inc
APH	Aphria Inc	FIRE	Supreme Pharmaceuticals Inc
ACB	Aurora Cannabis Inc	ZOM	Zomedica Pharmaceuticals Corp



EARNINGS

EARNINGS

7


Currency in CAD

NEUTRAL OUTLOOK: Mixed earnings expectations and performance.

Earnings Score Averages

Pharmaceuticals Group: **5.3** Mid Market Cap: **6.3**
Pharma. & Med. Research Sector: **5.1** TSX Comp Index: **6.3**

Earnings Score Trend (4-Week Moving Avg)




Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
WEED	5	6	8	6	7	
MJN	NR	10	7	7	3	
ACB	NR	NR	NR	NR	NR	
FIRE	NR	NR	NR	NR	NR	
ICC	NR	NR	NR	NR	NR	

EARNINGS INDICATORS

Earnings Surprises (33.3% weight)

Estimate Revisions (33.3% weight)

Recommendation Changes (33.3% weight)



Last 4 Years

# Positive Surprises (> 2%)	1
# Negative Surprises (< -2%)	2
# In-Line Surprises (within 2%)	0
Avg Surprise	-16.7%

Last 4 Weeks

# Up Revisions	0
# Down Revisions	0
Avg Up Revisions	0.0%
Avg Down Revisions	0.0%

Last 120 Days


# Broker Upgrades	0
# Broker Downgrades	0

HIGHLIGHTS

- Canopy Growth Corp currently has an Earnings Rating of 7. The average Earnings Rating for its Pharmaceuticals industry is 5.3 and the S&P/TSX COMPOSITE index average is 6.1.
- WEED's current quarter consensus estimate has remained relatively unchanged over the past 90 days at -0.02. Estimates within its industry have moved an average of -4.0% during the same time period.
- During the past four weeks, analysts covering WEED have made no upward or downward EPS estimate revisions for the current quarter.

PRICE TARGET

The chart indicates where analysts predict the stock price will be within the next 12 months, as compared to the current price.



12-Month Price Target


Mean	13.30
High	16.00
Low	10.00
Target vs. Current	55.4%
# of Analysts	9




EARNINGS PER SHARE

Earnings per share (EPS) is calculated by dividing a company's earnings by the number of shares outstanding. Analysts tend to interpret a pattern of increasing earnings as a sign of strength and flat or falling earnings as a sign of weakness.

The charts provide a comparison between a company's actual and estimated EPS, including the high and low forecasts.



Quarterly	17-03	17-06
Mean	-0.047	-0.010
High	-0.030	-0.010
Low	-0.080	-0.010
# of Analysts	3	1



Annual	2017	2018
Mean	-0.022	-0.026
High	0.000	0.090
Low	-0.050	-0.130
# of Analysts	5	5

MEAN ESTIMATE TREND


	Q 17-03	Q 17-06	Y 2017	Y 2018	Price Target
Current	-0.047	-0.010	-0.022	-0.026	13.30
30 Days Ago	-0.047	-0.025	-0.022	-0.024	14.10
90 Days Ago	-0.047	-0.025	-0.022	-0.024	13.90
% Change (90 Days)	0.0%	60.0%	0.0%	-8.3%	-4.3%

Current Fiscal Year End: 17-03

Next Expected Report Date: 2017-06-28

ANALYST RECOMMENDATIONS

Thomson Reuters I/B/E/S Mean: **Buy** (9 Analysts)



EARNINGS SURPRISES

Comparing a company's actual earnings to the mean expectation of analysts results in a difference referred to as a 'positive' or 'negative' surprise. Research has shown that when a company reports a surprise, it is often followed by more of the same surprise type.

Surprise Summary (Last 6 Years)


Surprise Type	Amount	Percent
Positive Years (> 2%)	1	33.3%
Negative Years (< -2%)	2	66.7%
In-Line Years (within 2%)	0	--

Surprise Detail (Last 6 Periods)

Surprise Type	Announce Date	Period End Date	Actual EPS	Mean EPS	Surprise (%)
Positive	2016-06-27	2016-03-31	-0.010	-0.110	90.9%
Negative	2015-06-29	2015-03-31	-0.290	-0.180	-61.1%
Negative	2015-02-26	2014-12-31	-0.300	-0.175	-71.4%

ANNUAL REVENUE


A pattern of increasing sales in conjunction with a rising EPS may influence a buy recommendation, while flat or falling sales and faltering earnings may explain a sell recommendation. A rising EPS with flat or falling sales may result from increased cost efficiency and margins, rather than market expansion. This chart shows the sales forecast trend of all analysts and the highest and lowest projections for the current and next fiscal year.



	2017	2018
Mean	41.9M	122.7M
High	44.8M	140.4M
Low	40.2M	99.4M
Forecasted Growth	229.8%	866.1%
# of Analysts	8	8



FUNDAMENTAL




POSITIVE OUTLOOK: Strong fundamentals such as high profit margins, low debt levels, or growing dividends.

Fundamental Score Averages

Pharmaceuticals Group: 5.6
Pharma. & Med. Research Sector: 5.1
Mid Market Cap: 7.6
TSX Comp Index: 7.9

Fundamental Score Trend



Peers	Q2 2016	Q3 2016	Q4 2016	Q1 2017	Current	3Y Trend
FIRE	NR	NR	NR	NR	10	
WEED	7	5	7	NR	8	
ACB	7	8	6	NR	7	
MJN	3	2	2	NR	2	
ICC	1	1	1	NR	1	


FUNDAMENTAL INDICATORS

Profitability (25% weight)

Debt (25% weight)

Earnings Quality (25% weight)

Dividend (25% weight)



Revenue Growth For year over year ending 2016-03	569.4%	Current Ratio For interim period ending 2016-12	10.9	Oper. Cash Yield For latest 12 months ending 2016-12	-18.5%	Dividend Growth For year over year ending 2016-03	0.0%
Gross Margin For latest 12 months ending 2016-12	-58.7%	Debt-to-Capital For annual period ending 2016-03	2.7%	Accruals For latest 12 months ending 2016-12	-13.1%	Dividend Payout For latest 12 months ending 2016-12	0.0%
Return On Equity For interim period ending 2016-12	-0.3%	Interest Funding For interim period ending 2016-06	-0.6%	Days Sales In Inv. For annual period ending 2016-03	190.0	Dividend Coverage For annual period ending --	--
Net Margin For latest 12 months ending 2016-12	-2.1%	Interest Coverage For interim period ending 2016-12	21.3	Days Sales In Rec. For annual period ending 2016-03	32.5	Current Div. Yield For latest 12 months ending 2017-06	--

HIGHLIGHTS

- The Fundamental Rating for Canopy Growth Corp improved significantly over the last quarter from 5 to 8. The current rating is considerably more bullish than the Pharmaceuticals industry group average of 5.6.
- WEED's gross margin of -58.7% is substantially below the Pharmaceuticals industry group average of 47.5%.
- The company's current ratio has been higher than its industry group average for each of the past five years.
- The operating cash yield for WEED is the lowest within its Pharmaceuticals industry group.
- Canopy Growth Corp does not currently pay a dividend. Of 40 firms within the Pharmaceuticals industry group, it is among the 40 companies without a dividend.




RELATIVE VALUATION



NEGATIVE OUTLOOK: Multiples significantly above the market or the stock's historic norms.

Relative Valuation Score Averages

Pharmaceuticals Group:	4.1	Mid Market Cap:	4.9
Pharma. & Med. Research Sector:	3.7	TSX Comp Index:	4.9




Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
WEED	3	3	3	3	3	
MJN	1	1	2	2	2	
ACB	2	NR	NR	NR	NR	
FIRE	NR	NR	NR	NR	NR	
ICC	NR	NR	NR	NR	NR	

RELATIVE VALUATION INDICATORS

Forward PEG (50% weight)

Trailing PE (25% weight)

Forward PE (25% weight)



Indicator	WEED	Peer Group	Indicator	WEED	Peer Group	
Price to Sales	44.1	MJN	Trailing PE	--	Forward PE	--
5-Yr Average	20.0	ACB	5-Yr Average	--	5-Yr Average	--
Rel. to 5-Yr Avg.	>100% Premium	FIRE	Rel. to 5-Yr Avg.	--	Rel. to 5-Yr Avg.	--
TSX Comp Index	1.7	ICC	TSX Comp Index	21.9	TSX Comp Index	16.4
Rel. to TSX Comp	>100% Premium	MJN	Rel. to TSX Comp	--	Rel. to TSX Comp	--

HIGHLIGHTS


- Canopy Growth Corp currently has a Relative Valuation Rating of 3 which is significantly below the S&P/TSX COMPOSITE index average rating of 4.9.
- WEED's Price to Sales ratio of 44.1 represents a >100% Premium to its 5-year average of 20.0.



PRICE TO SALES

The most recent week's close price divided by the revenue per share.


Price to Sales: 44.1
5-Year Average: 20.0
TSX Comp Index Average: 1.7
Pharmaceuticals Group Average: 1.2



TRAILING PE

The most recent week's close price divided by the sum of the four most recently reported quarterly earnings.


Trailing PE: --
5-Year Average: --
TSX Comp Index Average: 21.9
Pharmaceuticals Group Average: --



FORWARD PE

The most recent week's close price divided by the sum of the four upcoming quarterly consensus estimates.


Forward PE: --
5-Year Average: --
TSX Comp Index Average: 16.4
Pharmaceuticals Group Average: 11.7



FORWARD PEG

The Forward P/E divided by the five-year forecasted growth rate.

Forward PEG: --
5-Year Average: --
TSX Comp Index Average: 1.0
Pharmaceuticals Group Average: --



RISK




NEUTRAL OUTLOOK: Moderate risk (medium volatility).

Risk Score Averages

Pharmaceuticals Group:	5.4	Mid Market Cap:	8.4
Pharma. & Med. Research Sector:	4.7	TSX Comp Index:	8.5

Risk Score Trend (4-Week Moving Avg)



Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
WEED	4	7	7	7	7	
ICC	NR	8	6	5	5	
MJN	6	6	5	5	5	
ACB	4	6	4	3	3	
FIRE	NR	NR	NR	NR	NR	


RISK INDICATORS

Magnitude Of Returns (25% weight)

Volatility (25% weight)

Beta (1-year) (25% weight)

Correlation (25% weight)



Daily Returns (Last 90 Days)		Standard Deviation		Beta vs. TSX Comp		Correlation vs. TSX Comp	
Best	11.1%	Last 90 Days	3.65	Positive Days Only	1.16	Last 90 Days	11%
Worst	-7.1%	Last 60 Months	23.13	Negative Days Only	1.22	Last 60 Months	23%
Monthly Returns (Last 60 Months)		Intra-Day Swing (Last 90 Days)		Beta vs. Group		Correlation vs. Group	
Best	80.2%	Average	4.7%	Positive Days Only	-0.08	Last 90 Days	-5%
Worst	-22.5%	Largest	14.2%	Negative Days Only	2.28	Last 60 Months	27%

HIGHLIGHTS

- Canopy Growth Corp currently has a Risk Rating of 7 while the S&P/TSX COMPOSITE index has an average rating of 8.5.
- On days when the market is up, WEED shares tends to outperform the S&P/TSX COMPOSITE index. However, on days when the market is down, the shares generally decrease by more than the index.
- In the short term, WEED has shown low correlation (≥ -0.1 and < 0.2) with the S&P/TSX COMPOSITE index. The stock has, however, shown average correlation (≥ 0.2 and < 0.4) with the market in the long term.
- Over the last 90 days, WEED shares have been more volatile than the overall market, as the stock's daily price fluctuations have exceeded that of 98% of S&P/TSX COMPOSITE index firms.

RISK ANALYSIS

Peers	Last 90 Days				Last 60 Months		
	Best Daily Return	Worst Daily Return	# Days Up	# Days Down	Largest Intra-Day Swing	Best Monthly Return	Worst Monthly Return
WEED	11.1%	-7.1%	25	38	14.2%	80.2%	-22.5%
ACB	17.5%	-8.5%	29	31	26.6%	246.4%	-26.7%
FIRE	2540%	-7.4%	18	30	15.9%	--	--
ICC	31.9%	-15.4%	25	31	34.9%	42.9%	-68.0%
MJN	13.4%	-11.5%	21	40	17.8%	93.5%	-25.0%
TSX Comp	1.2%	-1.7%	29	33	1.6%	4.9%	-6.3%



PRICE MOMENTUM

PRICE MOMENTUM
4


Currency in CAD

NEUTRAL OUTLOOK: Performance relatively in-line with the market.

Price Momentum Score Averages

Pharmaceuticals Group:	6.1	Mid Market Cap:	5.7
Pharma. & Med. Research Sector:	4.7	TSX Comp Index:	5.6

Price Momentum Score Trend (4-Week Moving Avg)




Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
FIRE	NR	NR	NR	10	10	
ICC	10	7	8	6	9	
ACB	9	8	5	5	4	
WEED	9	7	2	4	4	
MJN	10	9	5	3	3	

PRICE MOMENTUM INDICATORS

Relative Strength (70% weight)

Seasonality (30% weight)



Relative Strength Indicator (Scale from 1 to 100)

	WEED	Industry Avg
Last 1 Month	52	49
Last 3 Months	49	51
Last 6 Months	51	52


Average Monthly Return (Last 10 Years)

	JUN	JUL	AUG
Company Avg	2.2%	-3.8%	-9.1%
Industry Avg	-2.7%	3.7%	-0.9%
Industry Rank	62 of 75	5 of 76	46 of 76

PRICE PERFORMANCE

Daily close prices are used to calculate the performance of the stock as compared to a relevant index over five time periods.

WEED
TSX Mid



	WEED	TSX Mid
Close Price (2017-06-22)	8.56	963
52-Week High	17.86	1,002
52-Week Low	2.62	898

- Canopy Growth Corp has a Price Momentum Rating of 4, which is significantly lower than the Pharmaceuticals industry average rating of 6.1.
- On 2017-06-22, WEED closed at 8.56, 52.1% below its 52-week high and 226.7% above its 52-week low.
- WEED shares are currently trading 2.1% above their 50-day moving average of 8.38, and 5.7% below their 200-day moving average of 9.08.



DETAILED STOCK REPORT TIPS

The Thomson Reuters Stock Report is a comprehensive, company-specific analysis that includes a proprietary Stock Rating along with underlying component indicators and supportive data elements. The report is updated daily, although some of the data elements and the ratings are updated weekly.

Average Score

The Average Score combines a quantitative analysis of five widely-used investment decision making tools - Earnings, Fundamental, Relative Valuation, Risk, and Price Momentum. First, a simple average of the five underlying component ratings is calculated. Then, a normal distribution is used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A score of 8 to 10 is considered positive, 4 to 7 is neutral, and 1 to 3 is negative. These five factors may be evaluated differently using alternative methodologies, and the importance of individual factors varies across industry groups, market capitalization and investment styles. Additional criteria should always be used to evaluate a stock.

A company must have sufficient data available for at least three of the five component indicators in order to receive an overall Average Score. Approximately 85% of the stocks within the coverage universe meet the criteria to generate a score.

Indicator Components

The five indicators that comprise the stock rating are displayed. Like the stock rating, the component rating scale is 1 to 10, with 10 being best. A company will receive an 'NR' for No Rating if the required data elements or criteria are not met. A detailed section for each component is included in the report.

Indicator Trends

Within each component section, historical score trends are displayed, typically using a 4-week moving average over a timeframe of the past three years. The dotted orange line indicates the average of the scores over those three years. The most recent occurrences of the best and worst scores are also displayed on the chart in grey boxes to put the current score into historical context.

Next to the trend chart for the company, current score averages are included, along with peer company comparisons of values from 6 months ago, 3 months ago, 1 month ago, the most recent value from 1 week ago, and the current score. The four closest industry peers are presented based on similar market capitalization.

Peer Analysis

The Thomson Reuters Business Classification (TRBC) system is used for industry comparisons. It is designed to track and display the primary business of a corporation by grouping together correlated companies that offer products and services into similar end markets. The system includes 10 Economic Sectors, 28 Business Sectors, 54 Industry Groups, and 136 Industries.

The Peer Analysis section of the report compares the company to its ten closest peers. The peers are selected from the industry based on similar market capitalization. The peer listing may have fewer than ten companies if there are fewer than ten companies within that industry classification.

Highlights

The Thomson Reuters proprietary automated text-generation system creates highlights summarizing the most noteworthy data. The bullets will vary by company and will change from week to week as different criteria are met.

Earnings

The Earnings Rating is based on a combination of three factors: earnings surprise, estimate revision, and recommendation changes. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have at least two of the three earnings factors in order to receive a score.

Earnings Surprises - The number of positive and negative surprises within the last 4 periods (quarters or years).

Estimate Revisions - The number of up and down revisions and the average percentage change of those revisions within a 4 week period.

Recommendation Changes - The number of broker upgrades and downgrades in the last 120 days.

Price Target

The price target is based on the predictions of analysts covering the stock and shows the high, low and mean price expected within the next 12 months.

Earnings Per Share

The quarterly and annual earnings per share are presented when available, along with the mean, high and low. Quarterly data is displayed for the past 4 quarters (actual) and the next 2 quarters (estimated). Annual data is displayed for the past 2 years (actual) and the next 2 years (estimated).

Mean Estimate Trend

The mean estimates show how the consensus has changed over the past 30 days and 90 days for the upcoming two quarters (when available) and two years. The percentage change is calculated for the company as a means for comparison by measuring the difference between the current consensus estimate and that of 90 days ago.

Analyst Recommendations

The I/B/E/S Mean is the mean recommendation of all analysts covering the stock, as provided by Thomson Reuters I/B/E/S (Institutional Brokers Estimate System). The recommendations are presented on a five-point standardized scale: strong buy, buy, hold, reduce, and sell.

Earnings Surprises

The surprise summary includes the total number of time periods (and percentage) in the last 12 quarters (quarterly) or last 4 years (annual) in which earnings surprises were positive, negative, or in-line. In order to be recognized as a positive or negative surprise, the percent must be greater than 2% above or 2% below the consensus, respectively.

The surprise detail section includes a listing of the company's quarterly earnings reported for the most recent 6 periods (quarters or years). The consensus analyst estimate is provided to determine if the actual earnings report represented a positive surprise, negative surprise, or in-line result.

Fundamental

The Fundamental Rating is based on a combination of four fundamental component factors: profitability, debt, earnings quality, and dividend. Companies that do not pay a dividend are not penalized. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have at least three of the four fundamental factors present in order to receive a score.

Profitability is comprised of four data elements.

- Revenue Growth: (Net Sales – Previous Net Sales) / Previous Net Sales
- Gross Margin: Gross Profit / Net Sales
- Return on Equity: Net Income / Total Equity
- Net Margin: Net Profit / Net Sales

Debt is comprised of four data elements.

- Current Ratio: Current Assets / Current Liabilities
 - Debt-to-Capital: Total Debt / Total Capital
 - Interest Funding: Interest Expense / Operating Cash Flow
 - Interest Coverage: (Pre-Tax Income + Interest Expense) / Interest Expense
- Earnings Quality is comprised of two data elements.
- Days Sales in Inventory: 365 / (Cost of Goods Sold / Inventory)
 - Days Sales in Receivables: 365 / (Net Sales (Revenues) / Receivables)

Dividend is comprised of four data elements. The company must have a current dividend yield.

- Dividend Growth Rate: (Dividends per Share – Previous Dividends per Share) / Previous Dividends per Share
- Dividend Funding: Dividends / Operating Cash Flow
- Dividend Coverage: (Pre-Tax Income + Interest Expense) / (Interest Expense + Dividends)
- Dividend Yield: Annual Dividends per Share / Current Market Price per Share

Indicator Trend

The fundamental indicator trend displays either quarterly scores over the past three years or annual scores over the past six years, depending on the reporting periods for the country. The best and worst scores can be easily determined from the values shown on the chart for each quarter or year.

Relative Valuation

The Relative Valuation Rating is based on a combination of three component factors: Price to Sales (50% weight), Trailing P/E (25% weight), and Forward P/E (25% weight). After the weightings are considered to combine individual factors, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. These common valuation metrics are evaluated against the overall market, the index, and the company's own historic 5-year averages. A stock needs to have at least one of the three relative valuation factors in order to receive a score.

Price to Sales: Close Price / (Sales for 4 Quarters or 1 Year / Shares Outstanding)

Trailing P/E: Close Price / Most Recent 4 Quarters or 1 Year of Earnings

Forward P/E: Close Price / Upcoming 4 Quarters or 1 Year of Earnings

Valuation Averages

Negative values are excluded when calculating the averages. A maximum value of 100 is placed on Trailing P/E and Forward P/E, a maximum value of 5 is placed on Forward PEG, and a maximum value of 20 is placed on Price to Sales when calculating the averages. Higher values are rounded down to the maximum for the averages.



Valuation Multiples

The valuation multiples provide the Trailing P/E, Forward P/E, Forward PEG, and Price to Sales for the company and the S&P 500 index average. In addition, a comparison of the current company's values to its 5-year average and an industry average are presented. A discount occurs when the company's ratio is valued more favorably (lower) than that to which it is compared.

Risk

The Risk Rating displays stocks on a scale of 1 to 10 with 10 being awarded to the least risky stocks. It is derived by looking at a series of long-term (5-year) and short-term (90-day) stock performance measures including volatility, magnitude of returns, beta, and correlation. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market. A stock needs to have at least two of the four risk factors in order to receive a score.

Magnitude of Returns – The best / worst daily returns in the past 90 days and the best / worst monthly returns in the past 60 months.

Volatility – The standard deviation of the stock price over the last 90 days and last 60 months, along with the average and largest intra-day stock swing.

Beta – Measures the tendency of a security's returns to respond to swings in the market, based on the beta of the company versus the relevant index.

Correlation – Determines how closely the returns of the stock and the relevant index move together, measured over the last 90 days and last 60 months.

Risk Analysis

Price analysis for the company and the relevant index is provided over two time periods. Daily analysis is provided for the last 90 days, whereas monthly statistics are used for the last 60 months.

Price Momentum

The Price Momentum Rating is based on a combination of two technical performance factors: relative strength (70% weight) and seasonality (30% weight). After the weightings are considered to combine individual factors, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have data for the relative strength factor in order to receive a score.

Relative Strength – The relative strength of the company for the last 1 month, 3 months, and 6 months on a scale of 1 to 100.

Seasonality – The average monthly return (price performance) for the current month and next 2 months for the company and industry, over the past 10 years. A lower industry rank indicates a higher return.

Price Performance

Daily close prices are used to calculate the price performance of the stock. The performance of the relevant index is also displayed as a means of comparison.

DISCLAIMER

Thomson Reuters content ("TR Content") is the intellectual property of Thomson Reuters or its third party content providers. The copying, republication or redistribution of TR Content, including by framing or similar means is expressly prohibited without the prior written consent of Thomson Reuters. The TR content in this report does not constitute a recommendation to buy or sell securities of any kind or constitute investment advice. Past performance is not a guarantee of future results.

All information in this report is assumed to be accurate to the best of our ability. Thomson Reuters excludes all liability, to the maximum extent permitted by law, for any inaccuracies in the TR Content or for the consequences of your reliance on the TR Content. Investors should consider this report as only a single factor when making an investment decision.

